



10-1-97

UNITED STATES ENVIRONMENTAL PROTECTION AGENCY
WASHINGTON, D.C. 20460

OCT 1 1997

OFFICE OF
PREVENTION, PESTICIDES AND
TOXIC SUBSTANCES

MEMORANDUM

SUBJECT: Captan Q1* Revisited

FROM: William L. Burnam *WLB*

TO: Paula Deschamp

Thank you for pointing out a problem in our recent reanalysis of the Captan cancer potency measurement (Q1*).

Our previous memo (Fisher, Jan. 15, 1997), used the female mouse gastrointestinal tract glandular tumors from the low dose mouse study as the basis for the Q1* and then used the new 3/4 scaling factor instead of the old 2/3 factor.

The basis for the Q1* should have been based on the males in the high dose mouse study since the quality of low dose mouse study was questioned in our July 20, 1988, Captan Cancer Peer Report. The new Q1* of (3.6×10^{-3}) (mg/kg/day)⁻¹ was the geometric mean of the male mice (3.9×10^{-3}) and females (3.4×10^{-3}) and was used in the Captan PD4.

Based on our current practice of using the most sensitive sex (males) and the 3/4 scaling factor, the new Q1* that should be used in the RED is 2.4×10^{-3} (mg/kg/day)⁻¹.

cc:

Pettigrew

P. Chin